Loading
ABBV-706 is an experimental antibody-drug conjugate from AbbVie in phase 3 trials for non-small-cell lung cancer, with its target not yet stated publicly.
ABBV-706 is an antibody-drug conjugate developed by AbbVie. The sponsor describes its target as SEZ6 (seizure-related homolog 6), which OnCo does not yet have a target page for. The sponsor states: ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07365241 (A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer), in non-small-cell lung cancer. The largest, NCT07365241, plans to enrol 531 participants with primary completion expected 2030-09. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
ABBV-706 is described as a targeted antibody-drug conjugate; a trial exclusion criterion barring prior SEZ6-targeted ADC use indicates it targets SEZ6, given intravenously in small cell lung cancer, alone or combined with atezolizumab.
1.ABBV-706's antibody arm binds its target on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ABBV-706" OR ABSTRACT:"ABBV-706") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ABBV-706, not a curated reading list.
Shares A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer, Non-small-cell lung cancer and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan), Non-small-cell lung cancer and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.